Skip to menu Skip to content Skip to footer

A first-in-class oral peptide therapy for chronic visceral pain (CVP) in irritable bowel syndrome (IBS) (Externally led by SAHMRI) (2026-2028)

Experts

Associate Professor Markus Muttenthaler

Affiliate of Centre for Chemistry and Drug Discovery
Centre for Chemistry and Drug Discovery
Institute for Molecular Bioscience
Principal Research Fellow
Institute for Molecular Bioscience
Markus Muttenthaler
Markus Muttenthaler